Data are limited regarding the association between tumor lymphovascular invasion and survival for patients with papillary thyroid cancer (PTC). This study sought to examine lymphovascular invasion as an independent prognostic factor for patients with PTC undergoing thyroid resection. The National Cancer Data Base (2010-2011) was queried for patients with PTC who underwent total thyroidectomy or lobectomy. Patients were classified into two groups based on the presence/absence of lymphovascular invasion. Demographic, clinical and pathological features were evaluated for all patients. A Cox proportional hazards model was utilized to identify factors associated with survival. Results show that 45,415 patients met inclusion criteria; 11.6% had lymphovascular invasion. Patients with lymphovascular invasion were more likely to have larger tumors (2.8 cm vs 1.5 cm, P < 0.01), metastatic lymph nodes (74.1% vs 32.5%, P < 0.01), and distant metastases (3.0% vs 0.5%, P < 0.01). They were also more likely to receive radioactive iodine (69.3% vs 44.9%, P < 0.01). Unadjusted overall 5-year survival was lower for patients who had tumors with lymphovascular invasion (86.6% vs 94.5%) (log-rank P < 0.01). After adjustment, increasing patient age (HR = 1.06, P < 0.01), male gender (HR = 1.68, P < 0.01), presence of metastatic lymph nodes (HR = 1.77, P < 0.01), distant metastases (HR = 3.49, P < 0.01), and lymphovascular invasion (HR = 1.88, P < 0.01) were associated with compromised survival. For patients with lymphovascular invasion, treatment with RAI was associated with reduced mortality (HR = 0.43, P < 0.01). The presence of lymphovascular invasion among patients with PTC is independently associated with compromised survival. Patients who have PTC with lymphovascular invasion should be considered higher risk, and adjuvant RAI should be more strongly considered.
Introduction
Thyroid cancer is the fastest increasing cancer in the United States among both men and women, largely as a result of an increase in the incidence of papillary thyroid cancer (PTC), which now represents approxi mately 90% of all new cases (Sosa & Udelsman 2006 , Jillard et al. 2015 . PTC has an excellent prognosis, with a causespecific 10year survival rate of over 90% (Biersack & Grünwald 2005) . In general, optimal treatment includes thyroid resection, with or without administration of postoperative radioactive iodine (RAI).
The impact of lymphovascular invasion on survival is important for several cancers; it is an independent risk factor for survival in colorectal, urothelial and breast cancers (Lotan et al. 2005 , Meguerditchian et al. 2005 , Rovera et al. 2013 . Data regarding the impact of lymphovascular invasion (LVI) on patient outcomes in PTC have been limited, based primarily on small, retrospective institutional studies (Kim et al. 2006 , Girardi et al. 2013 . One single institution study by Kim et al., including 662 PTC patients, of whom 33 (5%) had LVI, found that there was a significant association between LVI and both lateral cervical lymph node metastases and an increased risk of disease recurrence.
The primary aim of this study was to look for a potential association between tumor LVI and survival for patients with PTC undergoing thyroid resection. Such an association is not recognized in current differentiated thyroid cancer staging systems, including UICC/AJCC TNM (Union for International Cancer Control/American Joint Commission on Cancer tumor, Data presented as n (%) unless otherwise specified. Percentages were calculated from patients with non-missing data, which may be less than the total number of patients in each category.
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nodes, metastases) (Edge et al. 2010) , the National Thyroid Cancer Treatment Cooperative Study (NTCTCS) (Sherman et al. 1998) , the European Organization for Research and Treatment of Cancer (EORTC) (Byar et al. 1979) , AGES (age, grade, extent, size) (Hay et al. 1987) , AMES (age, metastases, extent, size) (Cady & Rossi 1988) , and MACIS (metastases, age, completeness of resection, invasion locally, size) (Hay et al. 1993 , Dean & Hay 2000 , Adam et al. 2015 . Our secondary aim was to describe the treatment patterns employed in the United States for patients with PTC whose tumors have LVI. We hypothesized that LVI would be associated with patient outcomes and that more aggressive treatment for these tumors would be warranted.
Methods
The (Phillips 2015) . The institutional review board at our institution granted this study an exempt status.
The NCDB (2010-2011) was queried for all adult patients (age ≥18 years) with a diagnosis of papillary thyroid cancer. We limited our study cohort to patients who underwent total thyroidectomy or lobectomy. The cohort was divided into two principle study groups based on the presence or absence of LVI on surgical pathology. Patient variables extracted from the database included age at diagnosis, gender, race, annual income, insurance, year of diagnosis, distance traveled to treating institution, and comorbidity score. Annual income levels were assigned by the NCDB by linking a patient's zip code to the U.S. Census data for the year 2000. Comorbidity was represented by the modified Charlson/Deyo scoring system (Deyo et al. 1992) . Clinical and pathological variables of interest included tumor size, histological subtype, presence of multifocality, lymph node involvement, and NCDB cancer stage according to the AJCC/TNM system. All variables were summarized based on the presence or absence of LVI.
Statistical analysis
Baseline characteristics were reported using frequencies and proportions for categorical variables and mean and standard deviation for continuous variables. Data were compared using χ 2 and Student's t-tests. Overall survival was defined as the time from diagnosis to death or the last followup visit. Survival time was censored for patients alive at the end of the study period. Patients with zero months of followup evaluation were excluded from the study. Estimates and 95% confidence intervals (95% CI) of overall survival proportions were computed using the Kaplan-Meier method, and survival distributions were compared between study groups using the logrank test.
A multivariate Cox proportional hazards model was used to examine the adjusted association of LVI with overall survival. The model adjusted for the effects of patient age, gender, race, annual income, insurance status, facility type, tumor size, lymph node involvement, and treatment with radioactive iodine. To examine the effect of RAI use in combination with LVI on survival, a separate model was conducted that also included a RAI*LVI interaction term. A multivariate logistic regression model 
Results
In total, 45,415 patients met the inclusion criteria. Of these, 5284 (11.6%) patients had tumors with LVI. Overall, patients were more likely to be female than male, to be white rather than other races, and to have private insurance; the majority of patients were treated at academic and comprehensive facilities. Patients with LVI were more likely to be male and to have larger tumors (mean size of 2.8 vs 1.5 cm for patients without LVI, P < 0.01), metastatic cervical lymph nodes, Data presented as n (%) unless otherwise specified. Percentages were calculated from patients with non-missing data, which may be less than the total number of patients in each category.
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and distant metastases (Table 1) . They also had more advanced cancers (stages 3 and 4) and were more likely to undergo treatment at an academic medical center. Patients with LVI were also more likely to receive postoperative RAI. LVI was associated with other aggressive tumor characteristics, such as metastatic cervical lymph nodes (odds ratio (OR) = 3.00, 95% CI: 2.67-3.35, P < 0.01), distant metastases (OR = 3.65, 95% CI: 2.85-4.67, P < 0.01), extrathyroidal extension (OR = 4.61, 95% CI: 3.99-5.32, P < 0.01), multifocality (OR = 1.61, 95% CI: 1.52-1.71, P < 0.01), and aggressive histological variants (OR = 3.27, 95% CI: 2.76-3.88, P < 0.01). Other characteristics associated with LVI included male gender and government insurance ( Table 2) .
Among patients with LVI, males were older than females (age 51.6 vs females 45.9 years, P < 0.01) and had a larger average tumor size (mean size of 3.3 vs 2.6 cm, P < 0.01). Males were also more likely to have metastatic cervical lymph nodes (80.1% of males vs 71.5% of females, P < 0.01) and distant metastases (5.1% of males vs 2.2% of females, P < 0.01) (Table 3) . When the presence of LVI was analyzed by age (decade of life), younger and older patients had a higher rate of LVI than middleaged patients in the fifth to seventh decade of life (Fig. 1) .
LVI and survival in unadjusted analyses
The overall 5year survival for PTC was 93.6%. A KaplanMeier analysis was performed, and unadjusted overall survival was examined for patients with LVI compared with patients without LVI (logrank P < 0.01, 5year survival 86.6% vs 94.5%, respectively) (Fig. 2) . The 5year survival among patients aged >45 years was superior for patients without LVI (92.6%) compared with patients with LVI (76.2%, P < 0.01), and among patients aged ≤45 years, survival was similar (97.9% without LVI and 99.5% with LVI, P = 0.91; data not shown).
LVI and survival in adjusted analyses
After adjusting for patient demographic, clinical and pathological factors, including age, gender, race, insurance status, income, facility type, tumor size, lymph node status, presence of distant metastases, lobectomy, positive surgical margins, and extrathyroidal extension, the presence of LVI was associated with compromised survival (Hazard ratio (HR) = 1.88, 95% CI: 1.56-2.27, P < 0.01). Other factors associated with survival included increasing patient age (HR = 1.06 per year, 95% CI: 1.05-1.07, P < 0.01), male gender (HR = 1.68, 95% CI: 1.45-1.95, P < 0.01), presence of metastatic cervical lymph nodes (HR = 1.77, 95% CI: 1.35-2.32, P < 0.01), extrathyroidal extension (HR = 3.80, 95% CI: 2.94-4.91, P < 0.01), and distant metastases (HR = 3.49, 95% CI: 2.60-4.69, P < 0.01) ( Table 4) . In a subgroup analysis of tumors <1 cm in size, LVI was not associated with compromised survival (HR = 1.76, 95% CI: 1.00-3.10, P = 0.05). When using an interaction model, there was a significant interaction effect between LVI and RAI (interaction HR = 0.48, 95% CI: 0.41-0.56, P < 0.01). Patients with LVI in the presence of RAI (HR = 0.43, CI: 0.33-0.58, P < 0.01) had a greater reduction in mortality 
Discussion
To date, published data about the importance of LVI for outcomes among patients with PTC have been limited to small, retrospective, single institution studies (Kim et al. 2006 , Girardi et al. 2013 . This is the first study to examine the association between LVI and mortality for PTC in a nationwide database and to demonstrate that the presence of tumor LVI is associated with compromised patient survival. However, it is not included as a criterion to measure prognosis in any current thyroid staging systems.
Most studies to date assessing LVI have focused on disease recurrence (Kim et al. 2006 , Girardi et al. 2013 . In an analysis of 517 patients with PTC undergoing thyroidectomy at a single institution over 11 years, Girardi and coworkers reported LVI as an important risk factor for disease recurrence, as well as cervical lymph node metastasis (Girardi et al. 2013) . They also demonstrated that LVI was associated with more aggressive histological subtypes of PTC, such as the diffuse sclerosing, tall cell, and solid variants. In another study performed by Soydal and coworkers, 357 patients with papillary thyroid microcarcinomas (or PTC <1 cm) from a single institution underwent thyroidectomy (Soydal et al. 2015) ; 89 of these patients had LVI and/or capsular invasion. They demonstrated that LVI was associated with an increased risk of disease recurrence and metastasis (2.2% rate without LVI/capsular invasion, 9.2% rate with LVI/capsular invasion, P < 0.01). Although this study demonstrated an association between LVI and disease recurrence, it was limited to PTC <1 cm in diameter, and did not distinguish LVI as a separate prognostic factor from capsular invasion. Additionally, there are no known studies to date examining LVI as a predictor of mortality. Our study represents not only the largest cohort but also the only cohort, to date analyzing the association between LVI and survival using a large national dataset. It demonstrates that LVI is independently associated with compromised patient survival, observed even at relatively short followup times.
We also demonstrated that more aggressive tumor characteristics were associated with LVI, including positive lymph nodes, extrathyroidal extension and distant metastases. This is in agreement with several other studies that have established an association between LVI and cervical lymph node metastases (Merdad et al. 2012 , Sun et al. 2015 . In a systematic review, Sun and coworkers reviewed 20 studies and 9084 patients with PTC who underwent thyroidectomy with prophylactic lymph node dissection (Sun et al. 2015) . In this study, the authors found that there was an increased risk of central lymph node metastases in clinical N0 patients with LVI (OR = 4.35, 95% CI: 2.24-8.46, P < 0.01). Other factors were independently associated with central lymph node metastases, such as tumor size >2 cm (OR = 2.98, 95% CI: 2.08-4.28, P < 0.01), extrathyroidal extension (OR = 2.27, 95% CI: 1.76-2.94, P < 0.01), and capsular invasion (OR = 1.72, 95% CI: 1.39-2.41, P < 0.01); however, LVI had the greatest predictive value. LVI has also been shown to be associated with an increased risk of having lateral lymph node metastasis; Merdad et al. presented a series of 185 patients with PTC who underwent selective neck dissection and showed that tumor LVI (OR = 5.52, s.e.m. = 0.03, P = 0.03) was an independent risk factor for having level Vb nodal involvement (Merdad et al. 2012) .
Our data have shown that patients with LVI had an overall greater risk of mortality compared with those without LVI, and patients in extremes of age had more tumors with LVI than those who were in their fifth to seventh decade of life. The improved survival of those 
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without LVI continued to hold true when controlling for patient age. LVI is currently not part of any staging system for differentiated thyroid cancer. The UICC/AJCC TNM system is most widely used in the United States and includes tumor size, extrathyroidal extension, capsular invasion, vascular invasion, cervical and mediastinal lymph node involvement, and distant metastases (Edge et al. 2010) . Our multivariate analysis demonstrated that LVI is associated with compromised survival. The limitations of our study include those that are part of all studies involving large databases. There is a potential for coding errors, but the NCDB is standardized and highly audited. An additional limitation of this study is that NCDB only reports overall survival, without diseasespecific survival or recurrence data. Also, the NCDB does not include novel predictors of outcomes, such as molecular markers. As this study is observational, it is impossible to conclude that LVI is the cause of compromised survival. The strengths of our study lie in the large volume of patient data evaluated, as well as the contemporary populationbased data available.
Conclusion
In this study, we identified patients more likely to have PTC with LVI following total thyroidectomy or lobectomy, including males, patients in the extremes of age, larger tumor size, presence of metastatic cervical lymph nodes, and distant metastases. We further demonstrated that there is compromised survival for patients with LVI compared with patients without LVI. These results suggest that patients with LVI undergoing total thyroidectomy or lobectomy for PTC should be considered to be at higher risk for mortality, and LVI may be an important independent risk factor to include in future iterations of staging guidelines.
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